Literature DB >> 24559564

HIV in Europe.

Airi Põder1, Madli Haldre2.   

Abstract

In 2011, the estimated number of people living with HIV in Europe and Central Asia was 2.3 million. This is more than twice the 2001 figure. At the same time, approximately 50% of the infected people may not know their HIV status. The Europe/Central Asia region is one of only two regions in which HIV infections continue to increase. The estimated prevalence rate in the west and center of the region, however, has remained stable at 0.2%. The HIV epidemics in Eastern Europe and Central Asia are typically driven by unsafe drug injection and by onward transmission to the sexual partners of people who inject drugs. In the western part of the region, the epidemic remains concentrated among men who have sex with men and migrants from countries with generalized epidemics. Means of preventing and fighting HIV should, first and foremost, be directed to those parts of the population that are most exposed to the risk of the infection. Proceeding from the data presented, recommendations are given for ways of decreasing HIV prevalence in the region, such as promoting dialogue and awareness among multistakeholders, including policy makers, donors, and population groups most exposed to the infection.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24559564     DOI: 10.1016/j.clindermatol.2013.08.011

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


  2 in total

1.  Rectal Douching Among Men Who Have Sex with Men in Paris: Implications for HIV/STI Risk Behaviors and Rectal Microbicide Development.

Authors:  H Rhodes Hambrick; Su Hyun Park; William C Goedel; Jace G Morganstein; Noah T Kreski; Ofole Mgbako; Dustin T Duncan
Journal:  AIDS Behav       Date:  2018-02

2.  Development and Fidelity Testing of the Test@Work Digital Toolkit for Employers on Workplace Health Checks and Opt-In HIV Testing.

Authors:  Holly Blake; Sarah Somerset; Catrin Evans
Journal:  Int J Environ Res Public Health       Date:  2020-01-06       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.